Illumina, Inc. (ILMN) Receives $172.09 Average PT from Analysts

Illumina, Inc. (NASDAQ:ILMN) has been given a consensus rating of “Hold” by the twenty-four research firms that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $174.59.

A number of research firms have recently weighed in on ILMN. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $195.00 price target for the company in a research note on Thursday, July 27th. BidaskClub raised Illumina from a “sell” rating to a “hold” rating in a research note on Monday. Cowen and Company reaffirmed an “outperform” rating and set a $200.00 price target on shares of Illumina in a research note on Wednesday, August 2nd. First Analysis raised Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 price target for the company in a research note on Wednesday, August 2nd. Finally, Vetr downgraded Illumina from a “strong-buy” rating to a “hold” rating and set a $202.18 price objective on the stock. in a research note on Wednesday, August 2nd.

In other news, SVP Charles Dadswell sold 145 shares of Illumina stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $184.75, for a total transaction of $26,788.75. Following the sale, the senior vice president now owns 10,791 shares of the company’s stock, valued at approximately $1,993,637.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Michel Bouchard sold 246 shares of Illumina stock in a transaction that occurred on Thursday, June 8th. The stock was sold at an average price of $178.91, for a total value of $44,011.86. Following the sale, the insider now directly owns 19,139 shares in the company, valued at approximately $3,424,158.49. The disclosure for this sale can be found here. Insiders have sold a total of 134,639 shares of company stock worth $24,037,438 in the last three months. 1.60% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC raised its stake in shares of Illumina by 41.0% in the first quarter. Nisa Investment Advisors LLC now owns 6,190 shares of the life sciences company’s stock valued at $1,056,000 after buying an additional 1,800 shares during the last quarter. State of Tennessee Treasury Department raised its stake in shares of Illumina by 7.8% in the first quarter. State of Tennessee Treasury Department now owns 97,850 shares of the life sciences company’s stock valued at $16,697,000 after buying an additional 7,040 shares during the last quarter. Aberdeen Asset Management PLC UK raised its stake in shares of Illumina by 8.4% in the first quarter. Aberdeen Asset Management PLC UK now owns 27,981 shares of the life sciences company’s stock valued at $4,775,000 after buying an additional 2,158 shares during the last quarter. Bank of Nova Scotia raised its stake in shares of Illumina by 265.4% in the first quarter. Bank of Nova Scotia now owns 86,202 shares of the life sciences company’s stock valued at $14,710,000 after buying an additional 62,612 shares during the last quarter. Finally, Eastern Bank purchased a new stake in shares of Illumina during the first quarter valued at $256,000. 93.81% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Illumina, Inc. (ILMN) Receives $172.09 Average PT from Analysts” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.com-unik.info/2017/08/19/illumina-inc-ilmn-receives-172-09-average-pt-from-analysts-updated.html.

Illumina (ILMN) traded down 0.42% on Friday, hitting $198.74. 333,018 shares of the stock were exchanged. The company’s 50-day moving average is $174.66 and its 200-day moving average is $171.89. The company has a market cap of $29.02 billion, a PE ratio of 39.88 and a beta of 0.83. Illumina has a 52 week low of $119.37 and a 52 week high of $199.86.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The company had revenue of $662 million during the quarter, compared to the consensus estimate of $642.38 million. During the same period last year, the business earned $0.86 EPS. The business’s quarterly revenue was up 10.3% on a year-over-year basis. On average, analysts predict that Illumina will post $3.65 earnings per share for the current year.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

What are top analysts saying about Illumina Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Illumina Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit